Our group aims to improve diagnosis, risk stratification and treatment of patients with cutaneous lymphomas. These rare and heterogeneous malignancies pose important clinical challenges, from distinguishing lymphoma from inflammatory skin diseases to predicting disease progression and selecting the most appropriate treatment. We combine clinical and translational research with advanced technologies to better understand the biological and clinical diversity of these diseases and translate these insights into improved patient care. Our research spans computational pathology and artificial intelligence, molecular profiling and the tumour microenvironment, and is embedded in strong multidisciplinary and international collaborations.
